The UCLA Alzheimer's Disease Research Center (ADRC) supports cutting edge research in an environment that mentors junior investigators;attracts numerous researchers;hosts a pilot project program that allows investigators to gamer preliminary data for more advanced studies;collaborates with the National Alzheimer's Coordination Center (NACC) as well as other Alzheimer disease (AD) related investigators locally, nationally and internationally;extends AD research to women and minorities;and works closely with community and advocacy groups including the Alzheimer's Association. The UCLA ADRC is comprised of 6 cores and proposes 3 projects in this renewal application. Cores include: Administrative, Clinical, Data Management and Statistics, Neuropathology, Recruitment and Education, and Neuroimaging and Biomarkers. The three projects include an investigation of MRI techniques applicable to clinical trials and population studies (Project 1;Liana Apostolova;Junior Investigator), a study of the comparative information to be gained from FDDNP and Pittsburg Compound B molecular imaging and their relationship to CSF and plasma biomarkers (Project 2;Gary Small);and a study of antibodies that inhibit amyloid 6 and tau aggregation and may represent novel interventions in AD (Project 3;David Eisenberg). The Theme of the UCLA ADRC is The Therapeutic Imperative, emphasizing the urgency of developing new treatments for AD. Resource use, core organization, project selection, collaboration, and educational activities are prioritized according to their integration with the Center theme. Clinical Core is following 120 patients;Recruitment and Education Core sponsored lectures reaching 20,000 participants;Neuropathology Core performed autopsies on Center patients who died, and non-Center patients to augment tissue distribution. This application has a major emphasis on biomarkers as a key aspect of advancing new therapies for AD. A familial AD cohort is included in this renewal application and a new minority site (Harbor View Medical Center) has been added. Innovations in advancing research are proposed in each Core of this proposal. Each core has responded to criticisms and recommendations from the 2008 review in this renewal application.

Public Health Relevance

The UCLA ADRC theme of the Therapeutic Imperative reflects the commitment of UCLA investigators to shortening the time horizon to finding effective treatments for AD. Biomarkers are a key element in the search for effective therapies and will be advanced by investigators collaborating with the UCLA ADRC. Attracting minorities to research is critically important, and UCLA has been successful in this difficult task.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016570-15
Application #
8662619
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
1999-04-05
Project End
2015-03-31
Budget Start
2014-05-01
Budget End
2015-03-31
Support Year
15
Fiscal Year
2014
Total Cost
$1,896,670
Indirect Cost
$345,525
Name
University of California Los Angeles
Department
Neurology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Teng, Edmond; Chow, Nicole; Hwang, Kristy S et al. (2015) Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord 39:154-66
Hsiao, Julia J; Lu, Po H; Grill, Joshua D et al. (2015) Longitudinal declines in instrumental activities of daily living in stable and progressive mild cognitive impairment. Dement Geriatr Cogn Disord 39:24-Dec
Deutsch, Mariel B; Mendez, Mario F; Teng, Edmond (2015) Interactions between traumatic brain injury and frontotemporal degeneration. Dement Geriatr Cogn Disord 39:143-53
Sanchez-Juan, Pascual; Ghosh, Pia M; Hagen, Jayne et al. (2014) Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology 82:230-8
Burggren, Alison; Brown, Jesse (2014) Imaging markers of structural and functional brain changes that precede cognitive symptoms in risk for Alzheimer's disease. Brain Imaging Behav 8:251-61
Ringman, John M; Goate, Alison; Masters, Colin L et al. (2014) Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr Neurol Neurosci Rep 14:499
Ringman, John M; Sachs, Michael C; Zhou, Yan et al. (2014) Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 71:878-83
Grill, Joshua D; Zhou, Yan; Karlawish, Jason et al. (2014) Does study partner type impact the rate of Alzheimer's disease progression? J Alzheimers Dis 38:507-14
Ma, Qiu-Lan; Zuo, Xiaohong; Yang, Fusheng et al. (2014) Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci 34:7124-36
Apostolova, Liana G; Di, Li Jie; Duffy, Erin L et al. (2014) Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dement Geriatr Cogn Disord 37:315-26

Showing the most recent 10 out of 476 publications